Akarna Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akarna Therapeutics Ltd.
A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.
Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.
Option to acquire a company developing a CB1-targeted antibody for non-alcoholic steatohepatitis gets Johnson & Johnson into the race. Janssen’s James List explains how the NASH venture fits into J&J’s growing efforts in metabolic disease.